This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Celldex Therapeutics (CLDX) Q4 Earnings: What's in Store?
by Zacks Equity Research
Celldex Therapeutics, Inc. (CLDX) is expected to report fourth-quarter 2016 results on Mar 4 after market close.
Aerie Pharmaceuticals (AERI) Q4 Earnings: What to Expect?
by Zacks Equity Research
Aerie Pharmaceuticals, Inc. (AERI) is expected to report fourth-quarter 2016 results on Mar 7.
Biotech Stock Roundup: Kite Soars on CAR-T Data, EXEL in Immuno-Oncology Deals
by Arpita Dutt
Key updates this week include earnings results from companies like BioMarin and positive data on Kite's (KITE) lead pipeline candidate.
BioMarin (BMRN) Q4 Loss Narrower than Expected; Sales Beat
by Zacks Equity Research
BioMarin Pharmaceutical Inc. (BMRN) reported a loss of 37 cents per share in the fourth quarter of 2016.
Drug Stocks Q4 Earnings Slated for Feb 23: BMRN, ICPT & More
by Zacks Equity Research
The fourth-quarter earnings season is drawing to a close with results from 411 S&P 500 members or 82.2% of the index's total membership already out, as of Feb 22, 2017.
Biotech Stock Roundup: Alexion Reports 4Q Results, Celgene MS Drug Looks Promising
by Arpita Dutt
While Alexion (ALXN) reported a mixed quarter, Celgene provided promising data on a pipeline candidate.
BioMarin (BMRN) Q4 Earnings: Will it Post a Beat Again?
by Zacks Equity Research
We expect BioMarin Pharmaceutical Inc. (BMRN) to beat expectations when it reports fourth-quarter and full-year 2016 results on Feb 23
Can Wright Medical (WMGI) Surprise Investors in Q4 Earnings?
by Zacks Equity Research
Wright Medical Group N.V. (WMGI) is scheduled to release fourth-quarter 2016 results on Feb 21.
LabCorp (LH) Q4 Earnings: What's in the Cards for the Stock?
by Zacks Equity Research
Laboratory Corp. of America Holdings (LH), or LabCorp, is expected to report fourth-quarter 2016 results before the market opens on Feb 16.
What's in Store for ImmunoGen (IMGN) this Earnings Season?
by Zacks Equity Research
ImmunoGen, Inc. (IMGN) is scheduled to report results for the three months ended Dec 31, 2016 on Feb 17, before the opening bell. Overall, the company has posted an average negative surprise of 19.34%.
Will Zoetis (ZTS) Disappoint Estimates This Earnings Season?
by Zacks Equity Research
Zoetis Inc. (ZTS) is scheduled to report fourth-quarter and full year 2016 results on Feb 16 before the market opens.
Agios Pharmaceuticals (AGIO) Q4 Earnings: What's in Store?
by Zacks Equity Research
Agios Pharmaceuticals, Inc. (AGIO) is scheduled to report fourth-quarter and full-year 2016 results on Feb 16.
Perrigo Company (PRGO) Q4 Earnings: Disappointment in Store?
by Zacks Equity Research
Perrigo Company plc (PRGO) is expected to report fourth-quarter 2016 results this month. Perrigo has a mixed track record as the company beat expectations in two of the last four quarters and missed the same in the other two.
Teva (TEVA) Q4 Earnings: What's in Store for the Stock?
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) will be reporting fourth-quarter 2016 and full-year earnings on Feb 13, before the market opens.
5 Great Biotech Stocks to Buy Now
by Swarup Gupta
Biotechs have stabilized and still offer the potential to deliver substantial returns.
BioMarin's Hemophilia Candidate Included in PRIME Initiative
by Zacks Equity Research
BioMarin Pharmaceutical Inc. (BMRN) announced that BMN 270, being evaluated for the treatment for severe hemophilia A, has been granted access to Priority Medicines (PRIME), a regulatory initiative by the European Medicines Agency (EMA).
Is BioMarin (BMRN) Well Poised for Growth in 2017?
by Zacks Equity Research
We issued an updated research report on BioMarin Pharmaceutical Inc. (BMRN) on Jan 25.
The Zacks Analyst Blog Highlights: Sucampo Pharmaceuticals, Dr. Reddy's Laboratories, BioMarin Pharmaceutical and Repligen
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Sucampo Pharmaceuticals, Dr. Reddy's Laboratories, BioMarin Pharmaceutical and Repligen
3 Overlooked Drug Stocks to Watch Out for in 2017
by Arpita Dutt
As we start the New Year, here is a look at 3 drug stocks that have not been in the news much but have been witnessing upward estimate revisions and sport a strong Zacks Rank.
BioMarin (BMRN) Raised to Buy: Should You Add the Stock?
by Zacks Equity Research
The Zacks Investment Research upgraded BioMarin (BMRN) to a Zacks #2 Rank (Buy).
New Strong Buy Stocks for October 24th
by Indradip Ghosh
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday
New Strong Buy Stocks for October 17th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday
New Strong Buy Stocks for October 6th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
5 Biotech Stocks to Bet on This Earnings Season
by Zacks Equity Research
The happening biotech sector should be a good bet for investors.